Home Cart Sign in  
Chemical Structure| 150322-43-3 Chemical Structure| 150322-43-3

Structure of Prasugrel
CAS No.: 150322-43-3

Chemical Structure| 150322-43-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.

Synonyms: PCR 4099; CS 747; LY640315

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Prasugrel

CAS No. :150322-43-3
Formula : C20H20FNO3S
M.W : 373.44
SMILES Code : CC(OC1=CC2=C(CCN(C2)C(C(C3CC3)=O)C4=CC=CC=C4F)S1)=O
Synonyms :
PCR 4099; CS 747; LY640315
MDL No. :MFCD09954140
InChI Key :DTGLZDAWLRGWQN-UHFFFAOYSA-N
Pubchem ID :6918456

Safety of Prasugrel

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Prasugrel

GPCR

Isoform Comparison

Biological Activity

Target
  • P2Y receptor

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Experimental autoimmune myocarditis Oral gavage 100 µg/day Once daily for 29 days To evaluate potential benefits of P2Y12 receptor inhibition in myocarditis, results showed that prasugrel therapy preserved ejection fraction and significantly reduced platelet aggregates in the myocardium PMC8699761
Mice Thrombotic hindlimb ischemia model Oral 3 mg/kg/day Once daily for 23 days To evaluate the effects of prasugrel on blood flow reduction and gait abnormalities in a thrombotic hindlimb ischemia model. Results showed that prasugrel significantly inhibited blood flow reduction and gait abnormalities to levels found in P2Y12 deficient mice. PMC4859280
Mice Myocardial infarction model Oral 5 mg/kg body weight Once daily until the end of the experiment To evaluate the effect of the P2Y12 inhibitor prasugrel on the inflammatory response and cardiac function after myocardial infarction, results showed that prasugrel treatment reduced LSK cell cycle activity, decreased the inflammatory response, and preserved cardiac function. PMC8967792

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01178099 Anemia, Sickle Cell PHASE1 COMPLETED 2025-01-11 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, UK, SE 1 1YR, United Kingdom Less <<
NCT01951001 Acute Coronary Syndrome|Platel... More >>et Thrombus|Bleeding Less << PHASE4 COMPLETED 2025-10-18 Gyeonsang National University ... More >>Hospital, Jinju, Gyeonsangnam-do,, 660-702, Korea, Republic of Less <<
NCT01305369 Chronic Asthma PHASE4 COMPLETED 2025-12-11 Medicina 3 Ospedale San Paolo ... More >>Dipartimento di Medicina Chirurgia e Odontoiatria, Università di Milano, Milan, 20142, Italy Less <<
NCT01201772 Coronary Artery Disease PHASE4 COMPLETED 2025-09-11 University of Florida, Jackson... More >>ville, Florida, 32209, United States Less <<
NCT01476696 Sickle Cell Disease PHASE2 COMPLETED 2025-11-12 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakland, California, 94609, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, 20060, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, 60614, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, 70112, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, 02115, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, 63104, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, 27599, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, 45229, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, 15224, United States Less <<
NCT01591317 Healthy Volunteers PHASE1 COMPLETED 2025-05-09 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of Less <<
NCT03672097 Acute Coronary Syndrome (ACS) PHASE4 COMPLETED 2020-08-19 Kaohsiung Veterans General Hos... More >>pital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.68mL

0.54mL

0.27mL

13.39mL

2.68mL

1.34mL

26.78mL

5.36mL

2.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories